You are here

Our science / Clinical Trials / Find a Trial / NCT00257881

Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Back to Search Print Save as PDF Bookmark Trial

NCT00257881

Last updated on February 18, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Tokyo, Chuo-ku, 104-0045 Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20-74 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Malignant solid tumor progressed, or no standard treatment available

- Tumor expression of Lewis Y antigen

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Cancer therapy within 28 days before enrollment

- Pregnant or breastfeeding women

- Unstable or serious concurrent medical conditions

NCT00257881
Pfizer
Terminated
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Neoplasms
Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
NCT00940498
All Genders
18+
Years
Multiple Sites
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
NCT02078752
All Genders
18+
Years
Multiple Sites
Breast Neoplasms
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
NCT00435409
All Genders
18+
Years
Multiple Sites
Breast Neoplasms
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
NCT00036270
Females
50+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now